Bradykinin B2 receptors - A target in diabetic nephropathy

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 2, 2005, Pages 411-414

  Doggrell, Sheila A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Dogrell Biomedical Communications   (New Zealand)

Author keywords

ACE inhibitor; AVE7688; Bradykinin B2 receptor; Diabetic mice; Diabetic nephropathy; Icatibant; Vasopeptidase inhibition; Zucker diabetic rat

Indexed keywords

3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; ALBUMIN; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AVE 7688; BRADYKININ; BRADYKININ B2 RECEPTOR AGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ B3 RECEPTOR; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ICATIBANT; LABRADIMIL; LF 160687; LISINOPRIL; M 108048; NATRIURETIC FACTOR; OMAPATRILAT; PERINDOPRIL; RAMIPRIL; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

ARTICLE; CALCULATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE CONTROL; DRUG MECHANISM; ENZYME DEFECT; GENETIC POLYMORPHISM; GLOMERULOSCLEROSIS; HUMAN; HYPERTENSION; KIDNEY MASS; MESANGIUM; NONHUMAN; PATHOGENESIS; PREDICTION; PROTEIN TARGETING; PROTEINURIA; RAT STRAIN; RENAL PROTECTION; WESTERN HEMISPHERE;

ANIMALS; DIABETIC NEPHROPATHIES; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY FAILURE, CHRONIC; PROTEASE INHIBITORS; RECEPTOR, BRADYKININ B2;

EID: 18144427557     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.2.411     Document Type: Article

References (14)

1. KAKOKI M, TAKAHASHI N, JENNETTE JC, SMITHIES O: Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc. Natl. Acad. Sci. USA (2004) 101:13302-13305.
2. SCHÄFER S, SCHMIDTS H-L, BLEICH M, BUSCH A, LINZ W: Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. Br. J. Pharmacol. (2004) 143:27-32.
3. DOGGRELL SA: Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? Expert Opin. Pharmacother. (2002) 3:1543-1556.
4. MOGENSEN CE, NELDAM S, TIKKANEN I et al.: Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. (2000) 321:1440-1444.
5. HADJADJ S, BELLOUM R, BOUHANICK B et al.: Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in Type 1 diabetes mellitus: a prospective study. J. Am. Soc. Nephrol. (2001) 12:541-549.
6. FAVA S, AZZOPARDI J, ELLARD S, HATTERSLEY AT: ACE gene polymorphism as a prognostic indicator in patients with Type 2 diabetes and established renal disease. Diabetes Care (2001) 24:2115-2120.
7. HUANG W, GALLOIS Y, BOUBY N et al.: Genetically increased angiotensin 1-converting enzyme level and renal complications in the diabetic mouse. Proc. Natl. Acad. Sci. USA (2001) 98:13330-13334.
8. TAAL MW, NENOV VD, WONG W et al.: Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J. Am. Soc. Nephrol. (2001) 12:2051-2059.
9. TIKKANEN T, TIKKANEN I, ROCKWELL MD et al.: Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension (1998) 32:778-785.
10. DAVIS BJ, JOHNSTONE CI, BURRELL LM et al.: Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia (2003) 46:961-971.
11. SCHÄFER S, LINZ W, BUBE A et al.: Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty acids. Cardiovasc. Res. (2003) 60:447-454.
12. SCHÄFER S, LINZ W, VOLLERT H et al.: The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy. Diabetiologia (2004) 47:1264-1268.
13. MCCULLOUGH PA, JOSEPH K, MARTHUR VS: Diagnostic and therapeutic utility of B-type natiuretic peptide in patients with renal insufficiency and decompensated heart failure. Rev. Cardiovasc. Med. (2003) 4(Suppl.7):S3-S12.
14. MARCEAU F, REGOLI D: Bradykinin receptor ligands: therapeutic prospectives. Nat. Rev. Drug Discov. (2004) 3:845-852.